Carbamazepine-imatinib interaction in a child with chronic myeloid leukemia

Kazuaki Taguchi, Masahiko Kouroki, Takafumi Ohmura, Hirofumi Jono, Fumio Endo, Hideyuki Saito

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Imatinib mesylate, a selective tyrosine kinase inhibitor, is the frontline therapeutic agent used for the treatment of chronic myeloid leukemia (CML), and its therapeutic efficacy is associated with trough concentrations. Therefore, monitoring imatinib trough concentrations is strongly recommended for successful treatment of CML patients. It has been recently shown that some drugs altered imatinib plasma levels in adult patients. However, drug interactions with imatinib in children are still unknown. Here, we report a case of a 12-year-old child with epilepsy who was also diagnosed with CML and given imatinib in addition to an enzyme-inducing antiepileptic drug, carbamazepine. Compared to population kinetics data, the data obtained for the patient showed a significant decrease of imatinib plasma concentrations. Our findings suggest that monitoring imatinib plasma concentrations in children receiving enzyme-inducing antiepileptic drugs is needed to optimize the therapeutic efficacy of imatinib.

Original languageEnglish
Pages (from-to)e33-e36
JournalPediatrics International
Volume56
Issue number4
DOIs
Publication statusPublished - 2014 Jan 1
Externally publishedYes

Fingerprint

Carbamazepine
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Anticonvulsants
Therapeutics
Imatinib Mesylate
Enzymes
Drug Interactions
Protein-Tyrosine Kinases
Epilepsy
Pharmaceutical Preparations
Population

Keywords

  • Carbamazepine
  • Chronic myeloid leukemia
  • Drug interaction
  • Imatinib
  • Pharmacokinetics

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Carbamazepine-imatinib interaction in a child with chronic myeloid leukemia. / Taguchi, Kazuaki; Kouroki, Masahiko; Ohmura, Takafumi; Jono, Hirofumi; Endo, Fumio; Saito, Hideyuki.

In: Pediatrics International, Vol. 56, No. 4, 01.01.2014, p. e33-e36.

Research output: Contribution to journalArticle

Taguchi, Kazuaki ; Kouroki, Masahiko ; Ohmura, Takafumi ; Jono, Hirofumi ; Endo, Fumio ; Saito, Hideyuki. / Carbamazepine-imatinib interaction in a child with chronic myeloid leukemia. In: Pediatrics International. 2014 ; Vol. 56, No. 4. pp. e33-e36.
@article{0be363f5d5544464beaa5b2ec275ee4b,
title = "Carbamazepine-imatinib interaction in a child with chronic myeloid leukemia",
abstract = "Imatinib mesylate, a selective tyrosine kinase inhibitor, is the frontline therapeutic agent used for the treatment of chronic myeloid leukemia (CML), and its therapeutic efficacy is associated with trough concentrations. Therefore, monitoring imatinib trough concentrations is strongly recommended for successful treatment of CML patients. It has been recently shown that some drugs altered imatinib plasma levels in adult patients. However, drug interactions with imatinib in children are still unknown. Here, we report a case of a 12-year-old child with epilepsy who was also diagnosed with CML and given imatinib in addition to an enzyme-inducing antiepileptic drug, carbamazepine. Compared to population kinetics data, the data obtained for the patient showed a significant decrease of imatinib plasma concentrations. Our findings suggest that monitoring imatinib plasma concentrations in children receiving enzyme-inducing antiepileptic drugs is needed to optimize the therapeutic efficacy of imatinib.",
keywords = "Carbamazepine, Chronic myeloid leukemia, Drug interaction, Imatinib, Pharmacokinetics",
author = "Kazuaki Taguchi and Masahiko Kouroki and Takafumi Ohmura and Hirofumi Jono and Fumio Endo and Hideyuki Saito",
year = "2014",
month = "1",
day = "1",
doi = "10.1111/ped.12382",
language = "English",
volume = "56",
pages = "e33--e36",
journal = "Pediatrics International",
issn = "1328-8067",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Carbamazepine-imatinib interaction in a child with chronic myeloid leukemia

AU - Taguchi, Kazuaki

AU - Kouroki, Masahiko

AU - Ohmura, Takafumi

AU - Jono, Hirofumi

AU - Endo, Fumio

AU - Saito, Hideyuki

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Imatinib mesylate, a selective tyrosine kinase inhibitor, is the frontline therapeutic agent used for the treatment of chronic myeloid leukemia (CML), and its therapeutic efficacy is associated with trough concentrations. Therefore, monitoring imatinib trough concentrations is strongly recommended for successful treatment of CML patients. It has been recently shown that some drugs altered imatinib plasma levels in adult patients. However, drug interactions with imatinib in children are still unknown. Here, we report a case of a 12-year-old child with epilepsy who was also diagnosed with CML and given imatinib in addition to an enzyme-inducing antiepileptic drug, carbamazepine. Compared to population kinetics data, the data obtained for the patient showed a significant decrease of imatinib plasma concentrations. Our findings suggest that monitoring imatinib plasma concentrations in children receiving enzyme-inducing antiepileptic drugs is needed to optimize the therapeutic efficacy of imatinib.

AB - Imatinib mesylate, a selective tyrosine kinase inhibitor, is the frontline therapeutic agent used for the treatment of chronic myeloid leukemia (CML), and its therapeutic efficacy is associated with trough concentrations. Therefore, monitoring imatinib trough concentrations is strongly recommended for successful treatment of CML patients. It has been recently shown that some drugs altered imatinib plasma levels in adult patients. However, drug interactions with imatinib in children are still unknown. Here, we report a case of a 12-year-old child with epilepsy who was also diagnosed with CML and given imatinib in addition to an enzyme-inducing antiepileptic drug, carbamazepine. Compared to population kinetics data, the data obtained for the patient showed a significant decrease of imatinib plasma concentrations. Our findings suggest that monitoring imatinib plasma concentrations in children receiving enzyme-inducing antiepileptic drugs is needed to optimize the therapeutic efficacy of imatinib.

KW - Carbamazepine

KW - Chronic myeloid leukemia

KW - Drug interaction

KW - Imatinib

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=84961297020&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84961297020&partnerID=8YFLogxK

U2 - 10.1111/ped.12382

DO - 10.1111/ped.12382

M3 - Article

C2 - 25252068

AN - SCOPUS:84961297020

VL - 56

SP - e33-e36

JO - Pediatrics International

JF - Pediatrics International

SN - 1328-8067

IS - 4

ER -